Vagivital apotea. Apoteket AB expands the distribution of VagiVital® (English translation of the press release of yesterday) 2019-11-17

eVital

Having said all this, I can conclude that Peptonic is in an exciting development stage, and the current year will be at least as exciting as last year. Preparations to start selling VagiVital through webshops in Norway and Denmark are under way. Marketing, manufacturing, transport and distribution costs have increased considerably in 2018, not surprisingly, and were 4. The survey was performed during the period of December 2018 to mid January 2019. I want to express my sincere gratitude to the shareholders, to the Board members and advisors for all support and trust. Immaterial assets were reduced by 1.

ahintz.com

Thanks to a well executed marketing campaign, the interest for VagiVital among the pharmacy chains and on-line purchasing sites has grown quickly. Before this, VagiVital could be purchased on-line from e. I also want to thank my close colleagues for their massively valuable efforts during the year. The reception of the product was better than we could have hoped for. Capitalized patent-and development costs are estimated to result in future revenues for the company. It will be written in Swedish. No guarantees can be made that these statements are free from errors.

eVital

These results are well in line with those obtained in the clinical study, which is very satisfying. The agreement gives Yuanjia Bio exclusive rights to register, market and sell VagiVital® in China. The work to further broaden the distribution continues with highest priority. Thanks to the above capital injections our cash position is solid and means that we can go forward according to our marketing and development plans. Preparations are well under way and we expect the first patient to enter the study in April this year. In June, an agreement was signed with Orion Pharma concerning the distribution of VagiVital in Finland.

eVital

Feedback from the customers has been very positive. It is also important to expand the product portfolio of Peptonic. These statements should only be regarded as reflective of prevailing interpretations. The rights issue is 50 per cent guaranteed through subscription agreements and guarantee commitments. VagiVital®har genomgått ett kliniskt utvecklingsprogram i randomiserade, dubbelblinda studier och gett en kraftigt positiv behandlingseffekt — både på objektiva t. In October, Peptonic received the first product order from Orion Pharma. Yuanjin Bio will bear the costs of registration, launch and marketing of VagiVital.

Peptonic Medical : Year End Report

We are actively working on expanding distribution of VagiVital within and outside Europe. Hence, we are continously evaluating different products — both those found through our own search and those offered to us. Preparations are well under way and we expect the first patient to enter the study in April this year. Apoteket Hjärtat, Apotea, Apohem, and Meds. The order will be delivered to Orion during the first quarter 2019. We have developed a model and found a level of expenditure that feel optimal based on our resources, but are subject to adjustments based on outcomes and analyses.

Apoteket AB expands the distribution of VagiVital® (English translation of the press release of yesterday)

Patent and development costs are stated at acquisition value in the balance sheets. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions. I bolagets utvecklingsprogram finns även Vagitocin®- en produkt som innehåller oxytocin för behandling av vaginal atrofi. Marketing costs and costs of manufacturing, transport and distribution were approx. Utvecklingen av Bolaget framöver kommer främst ske genom ökade marknadsföringsinsatser, både i Sverige och till viss del internationellt. The order will be delivered to Orion during the first quarter 2019.

Year End Report

Marketing and promotion require capital. In some countries we will work with local distributors, whereas we plan to take a more active approach in other countries. Thanks to a well executed marketing campaign, the interest for VagiVital among the pharmacy chains and on-line purchasing sites has grown quickly. Among those women that had used VagiVital for more than two months, 89 percent reported significant symptom relief. The proceeds to Company amounted to 1. In June, the first patient of the clinical study was enrolled. Many activities are already fixed and many more are planned.

Year End Report

This high subscription rate indicates a high interest in the Peptonic share, and great expectations on Peptonic for the future. The launch has been delayed due to strategic considerations, but it will soon happen. It was very well tolerated and caused no serious adverse effects. This product candidate is in clinical development phase 2. To confirm this and to increase the awareness of VagiVital® among health care providers, a prospective clinical study will be performed with this patient group.

Peptonic Medical genomför företrädesemission om cirka 26,4 MSEK

One particular patient group with a high incidence and prevalence of vaginal atrophy are women that have undergone cancer treatment and are taking post treatment aromatase inhibitors. These results are well in line with those obtained in the clinical study, which is very satisfying. The rights issue is 50 per cent guaranteed through subscription agreements and guarantee commitments. Of those women who had used VagiVital® for two months or longer, nine out of ten reported symptom relief. The successful launch and our experiences from the Swedish market are very useful in these discussions. To build a trademark and get sales of a new product to take off require both investments and patience.

Interim report January to June 2019

The loan has to be paid back in July 2019. I want to express my sincere gratitude to the shareholders, to the Board members and advisors for all support and trust. All transactions between related parties are based on market conditions. A very positive event after the end of the period was the closure of a distribution agreement with Yuanjin Bio for China. En framgångsrik studie skulle innebära att Bolaget även kan marknadsföra VagiVitalâ som en alternativ behandlingsmetod utan östrogen med bevisad effekt vid vaginal atrofi, något som alltså i hög utsträckning drabbar personer som behandlats med antiöstrogener. About Peptonic Medical Peptonic Medical is an innovative Swedish medical development company. During July 2019, the number of shares increased by 31,782,076 shares to 127,128,306 shares following the registration of the new share issue.